In contrast, in all three recurrent GBM samples (bevacizumab-resistant) we detected a striking reduction in Nrp1 protein expression in tumor cells as well as in many intratumoral blood vessels (Fig 5D–5F). This evidence concerns the gene NRP1 and glioblastoma.